Priorities for cancer research in low- and middle-income countries: a global perspective.
Journal
Nature medicine
ISSN: 1546-170X
Titre abrégé: Nat Med
Pays: United States
ID NLM: 9502015
Informations de publication
Date de publication:
04 2022
04 2022
Historique:
received:
22
12
2021
accepted:
09
02
2022
entrez:
20
4
2022
pubmed:
21
4
2022
medline:
22
4
2022
Statut:
ppublish
Résumé
Cancer research currently is heavily skewed toward high-income countries (HICs), with little research conducted in, and relevant to, the problems of low- and middle-income countries (LMICs). This regional discordance in cancer knowledge generation and application needs to be rebalanced. Several gaps in the research enterprise of LMICs need to be addressed to promote regionally relevant research, and radical rethinking is needed to address the burning issues in cancer care in these regions. We identified five top priorities in cancer research in LMICs based on current and projected needs: reducing the burden of patients with advanced disease; improving access and affordability, and outcomes of cancer treatment; value-based care and health economics; quality improvement and implementation research; and leveraging technology to improve cancer control. LMICs have an excellent opportunity to address important questions in cancer research that could impact cancer control globally. Success will require collaboration and commitment from governments, policy makers, funding agencies, health care organizations and leaders, researchers and the public.
Identifiants
pubmed: 35440716
doi: 10.1038/s41591-022-01738-x
pii: 10.1038/s41591-022-01738-x
pmc: PMC9108683
mid: NIHMS1804393
doi:
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
649-657Subventions
Organisme : World Health Organization
ID : 001
Pays : International
Organisme : Cancer Research UK
ID : 29186
Pays : United Kingdom
Organisme : Medical Research Council
ID : MR/W023903/1
Pays : United Kingdom
Organisme : NCI NIH HHS
ID : P30 CA008748
Pays : United States
Informations de copyright
© 2022. Springer Nature America, Inc.
Références
Goss, P. E. et al. Challenges to effective cancer control in China, India, and Russia. Lancet Oncol. 15, 489–538 (2014).
doi: 10.1016/S1470-2045(14)70029-4
pubmed: 24731404
Mallath, M. K. et al. The growing burden of cancer in India: epidemiology and social context. Lancet Oncol. 15, e205–e212 (2014).
doi: 10.1016/S1470-2045(14)70115-9
pubmed: 24731885
International Agency for Research on Cancer, WHO. Cancer Tomorrow. Global Cancer Observatory https://gco.iarc.fr/tomorrow/en (2021).
Soerjomataram, I. & Bray, F. Planning for tomorrow: global cancer incidence and the role of prevention 2020–2070. Nat. Rev. Clin. Oncol. 18, 663–672 (2021).
doi: 10.1038/s41571-021-00514-z
pubmed: 34079102
Gelband, H. et al. Costs, affordability, and feasibility of an essential package of cancer control interventions in low-income and middle-income countries: key messages from Disease Control Priorities, 3rd edition. Lancet 387, 2133–2144 (2016).
doi: 10.1016/S0140-6736(15)00755-2
pubmed: 26578033
Heneghan, C. et al. Evidence for non-communicable diseases: analysis of Cochrane reviews and randomised trials by World Bank classification. BMJ Open 3, e003298 (2013).
doi: 10.1136/bmjopen-2013-003298
pubmed: 23833146
pmcid: 3703573
Wells, J. C. et al. An analysis of contemporary oncology randomized clinical trials from low/middle-income vs high-income countries. JAMA Oncol. 7, 379–385 (2021).
doi: 10.1001/jamaoncol.2020.7478
pubmed: 33507236
Rolfo, C. et al. Cancer clinical research in Latin America: current situation and opportunities. Expert opinion from the first ESMO workshop on clinical trials, Lima, 2015. ESMO Open 1, e000055 (2016).
doi: 10.1136/esmoopen-2016-000055
pubmed: 27843620
pmcid: 5070258
Van Hemelrijck, M. et al. Global cancer research in the era of COVID-19: a bibliometric analysis. ecancermedicalscience 15, 1264 (2021).
pubmed: 34567249
pmcid: 8426029
Seruga, B., Hertz, P. C., Le, L. W. & Tannock, I. F. Global drug development in cancer: a cross-sectional study of clinical trial registries. Ann. Oncol. 21, 895–900 (2010).
doi: 10.1093/annonc/mdp403
pubmed: 19815650
Drake, T. M., Knight, S. R., Harrison, E. M. & Søreide, K. Global inequities in precision medicine and molecular cancer research. Front. Oncol. 8, 346 (2018).
doi: 10.3389/fonc.2018.00346
pubmed: 30234014
pmcid: 6131579
Parkin, D. M. The evolution of the population-based cancer registry. Nat. Rev. Cancer 6, 603–612 (2006).
doi: 10.1038/nrc1948
pubmed: 16862191
Bray, F. et al. Cancer incidence in five continents: inclusion criteria, highlights from Volume X and the global status of cancer registration. Int. J. Cancer 137, 2060–2071 (2015).
doi: 10.1002/ijc.29670
pubmed: 26135522
Siddiqui, A. H. & Zafar, S. N. Global availability of cancer registry data. J. Glob. Oncol. 4, 1–3 (2018).
pubmed: 30085880
Ferlay, J. et al. Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods. Int. J. Cancer 144, 1941–1953 (2019).
doi: 10.1002/ijc.31937
pubmed: 30350310
Lopez, A. D., McLaughlin, D. & Richards, N. Reducing ignorance about who dies of what: research and innovation to strengthen CRVS systems. BMC Med. 18, 58 (2020).
doi: 10.1186/s12916-020-01526-9
pubmed: 32146906
pmcid: 7061482
Bray, F. et al. Planning and Developing Population-Based Cancer Registration in Low- or Middle-Income Settings (International Agency for Research on Cancer, 2014).
World Health Organization. WHO Civil Registration and Vital Statistics Strategic Implementation Plan 2021–2025 https://apps.who.int/iris/handle/10665/342847 (2021).
The Cancer Atlas. Cancer Surveillance https://canceratlas.cancer.org/taking-action/cancer-surveillance/ (2021).
Ramaswami, R. et al. Disparities in breast, lung, and cervical cancer trials worldwide. J. Glob. Oncol. 4, 1–11 (2018).
pubmed: 30241268
Wong, J. C., Fernandes, K. A., Amin, S., Lwin, Z. & Krzyzanowska, M. K. Involvement of low- and middle-income countries in randomized controlled trial publications in oncology. Global. Health 10, 83 (2014).
doi: 10.1186/s12992-014-0083-7
pubmed: 25498958
pmcid: 4273324
Nazha, B., Mishra, M., Pentz, R. & Owonikoko, T. K. Enrollment of racial minorities in clinical trials: old problem assumes new urgency in the age of immunotherapy. Am. Soc. Clin. Oncol. Educ. Book 39, 3–10 (2019).
doi: 10.1200/EDBK_100021
pubmed: 31099618
Phan, V. H. et al. Ethnic differences in drug metabolism and toxicity from chemotherapy. Expert Opin. Drug Metab. Toxicol. 5, 243–257 (2009).
doi: 10.1517/17425250902800153
pubmed: 19331590
Peng, L. et al. A meta-analysis comparing responses of Asian versus non-Asian cancer patients to PD-1 and PD-L1 inhibitor-based therapy. Oncoimmunology 9, 1781333 (2020).
Spratt, D. E. et al. Racial/ethnic disparities in genomic sequencing. JAMA Oncol. 2, 1070–1074 (2016).
doi: 10.1001/jamaoncol.2016.1854
pubmed: 27366979
pmcid: 5123755
Gadgil, D., Sengar, M., Pramesh, C. S., Badwe, R. & Ranganathan, P. Building research capacity in India: the Masters in Clinical Research program at the Tata Memorial Centre. Perspect. Clin. Res. 12, 189–192 (2021).
doi: 10.4103/picr.picr_48_21
pubmed: 34760645
pmcid: 8525792
Department for International Development. Capacity Building in Research https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/187568/HTN_Capacity_Building_Final_21_06_10.pdf (2021).
Sengar, M. et al. Medical oncology in India: workload, infrastructure, and delivery of care. Indian J. Med. Paediatr. Oncol. 40, 121–127 (2019).
doi: 10.4103/ijmpo.ijmpo_66_18
Ranganathan, P. et al. The International Collaboration for Research methods Development in Oncology (CReDO) workshops: shaping the future of global oncology research. Lancet Oncol. 22, 2369–2376 (2021).
doi: 10.1016/S1470-2045(21)00077-2
Malekzadeh, A., Michels, K., Wolfman, C., Anand, N. & Sturke, R. Strengthening research capacity in LMICs to address the global NCD burden. Glob. Health Action 13, 1846904 (2020).
doi: 10.1080/16549716.2020.1846904
pubmed: 33373280
pmcid: 7782223
Mittra, I. et al. Effect of screening by clinical breast examination on breast cancer incidence and mortality after 20 years: prospective, cluster randomised controlled trial in Mumbai. BMJ 372, n256 (2021).
doi: 10.1136/bmj.n256
pubmed: 33627312
pmcid: 7903383
Shastri, S. S. et al. Effect of VIA screening by primary health workers: randomized controlled study in Mumbai, India. J. Natl Cancer Inst. 106, dju009 (2014).
Badwe, R. et al. Locoregional treatment versus no treatment of the primary tumour in metastatic breast cancer: an open-label randomised controlled trial. Lancet Oncol. 16, 1380–1388 (2015).
doi: 10.1016/S1470-2045(15)00135-7
pubmed: 26363985
Badwe, R. et al. Single-injection depot progesterone before surgery and survival in women with operable breast cancer: a randomized controlled trial. J. Clin. Oncol. 29, 2845–2851 (2011).
doi: 10.1200/JCO.2010.33.0738
pubmed: 21670457
D’Cruz, A. K. et al. Elective versus therapeutic neck dissection in node-negative oral cancer. N. Engl. J. Med. 373, 521–529 (2015).
doi: 10.1056/NEJMoa1506007
pubmed: 26027881
Munung, N. S., Mayosi, B. M. & de Vries, J. Equity in international health research collaborations in Africa: perceptions and expectations of African researchers. PLoS ONE 12, e0186237 (2017).
doi: 10.1371/journal.pone.0186237
pubmed: 29036174
pmcid: 5643046
Boshoff, N. Neo-colonialism and research collaboration in Central Africa. Scientometrics 81, 413–434 (2009).
doi: 10.1007/s11192-008-2211-8
Binagwaho, A., Allotey, P., Sangano, E., Ekström, A. M. & Martin, K. A call to action to reform academic global health partnerships. BMJ 375, n2658 (2021).
doi: 10.1136/bmj.n2658
pubmed: 34725093
Parker, M. & Kingori, P. Good and bad research collaborations: researchers’ views on science and ethics in global health research. PLoS ONE 11, e0163579 (2016).
doi: 10.1371/journal.pone.0163579
pubmed: 27737006
pmcid: 5063577
Rodrigues, B. & Vanderpuye, V. Impact of the African Organisation for Research and Training in Cancer on improving cancer care on the continent: 15-year history. J. Glob. Oncol. 4, 152s (2018).
doi: 10.1200/jgo.18.52400
Pramesh, C. S. et al. Involvement of general public in biomedical research. Perspect. Clin. Res. 7, 152–155 (2016).
doi: 10.4103/2229-3485.192029
pubmed: 27843788
pmcid: 5079086
The UK Department for International Development. Research Capacity Strengthening in LMICs https://assets.publishing.service.gov.uk/media/5d42be4eed915d09d8945db9/SRIA_-_REA_final__Dec_2019_Heart___003_.pdf (2021).
Chandra, A., MacEwan, J. P., Campinha-Bacote, A. & Khan, Z. M. Returns to society from investment in cancer research and development. Forum Health Econ. Policy 19, 71–86 (2016).
doi: 10.1515/fhep-2014-0022
pubmed: 31419890
Hawkes, N. Cancer research provides a good economic return as well as health gains, report says. BMJ 348, g3973 (2014).
doi: 10.1136/bmj.g3973
pubmed: 24934966
Pramesh, C. S. et al. Delivery of affordable and equitable cancer care in India. Lancet Oncol. 15, e223–e233 (2014).
doi: 10.1016/S1470-2045(14)70117-2
pubmed: 24731888
Sullivan, R. et al. Cancer research in India: national priorities, global results. Lancet Oncol. 15, e213–e222 (2014).
doi: 10.1016/S1470-2045(14)70109-3
pubmed: 24731887
Coyle, C. et al. ADD-ASPIRIN: a phase III, double-blind, placebo controlled, randomised trial assessing the effects of aspirin on disease recurrence and survival after primary therapy in common non-metastatic solid tumours. Contemp. Clin. Trials 51, 56–64 (2016).
doi: 10.1016/j.cct.2016.10.004
pubmed: 27777129
pmcid: 5127874
Joharatnam-Hogan, N. et al. Aspirin as an adjuvant treatment for cancer: feasibility results from the Add-Aspirin randomised trial. Lancet Gastroenterol. Hepatol. 4, 854–862 (2019).
doi: 10.1016/S2468-1253(19)30289-4
pubmed: 31477558
André, N., Banavali, S., Snihur, Y. & Pasquier, E. Has the time come for metronomics in low-income and middle-income countries? Lancet Oncol. 14, e239–e248 (2013).
doi: 10.1016/S1470-2045(13)70056-1
pubmed: 23639324
Tannock, I. F. et al. Near-equivalence: generating evidence to support alternative cost-effective treatments. J. Clin. Oncol. 39, 950–955 (2021).
doi: 10.1200/JCO.20.02768
pubmed: 33555940
Irabor, O. C. et al. Can the adoption of hypofractionation guidelines expand global radiotherapy access? An analysis for breast and prostate radiotherapy. JCO Glob. Oncol. 6, 667–668 (2020).
doi: 10.1200/JGO.19.00261
pubmed: 32343628
Morris, M. J. et al. Phase III study of lutetium-177-PSMA-617 in patients with metastatic castration-resistant prostate cancer (VISION trial). J. Clin. Oncol. 39, LBA4 (2021).
Renner, A., Burotto, M. & Rojas, C. Immune checkpoint inhibitor dosing: can we go lower without compromising clinical efficacy? J. Glob. Oncol. 5, 1–5 (2019).
pubmed: 31348737
World Health Organization. The Selection and Use of Essential Medicines 2021 https://www.who.int/publications/i/item/WHO-MHP-HPS-EML-2021.01 (2021).
Szmulewitz, R. Z. et al. Prospective international randomized phase II study of low-dose abiraterone with food versus standard dose abiraterone in castration-resistant prostate cancer. J. Clin. Oncol. 36, 1389–1395 (2018).
doi: 10.1200/JCO.2017.76.4381
pubmed: 29590007
pmcid: 5941614
Patel, A. et al. Low-dose abiraterone in metastatic prostate cancer: is it practice changing? Facts and facets. JCO Glob. Oncol. 6, 382–386 (2020).
doi: 10.1200/JGO.19.00341
pubmed: 32125899
Are, C. et al. Promoting surgical research in the global south. Surgery 170, 1587–1588 (2021).
doi: 10.1016/j.surg.2021.02.006
pubmed: 33712308
Aggarwal, A. et al. Radiation therapy research: a global analysis 2001–2015. Int. J. Radiat. Oncol. Biol. Phys. 101, 767–778 (2018).
doi: 10.1016/j.ijrobp.2018.03.009
pubmed: 29976487
Damani, A. et al. Provision of palliative care in National Cancer Grid treatment centres in India: a cross-sectional gap analysis survey. BMJ Support. Palliat. Care https://doi.org/10.1136/bmjspcare-2019-002152 (2020).
Fojo, T., Mailankody, S. & Lo, A. Unintended consequences of expensive cancer therapeutics—the pursuit of marginal indications and a me-too mentality that stifles innovation and creativity: the John Conley Lecture. JAMA Otolaryngol. Head Neck Surg. 140, 1225–1236 (2014).
doi: 10.1001/jamaoto.2014.1570
pubmed: 25068501
Prasad, V., De Jesus, K. & Mailankody, S. The high price of anticancer drugs: origins, implications, barriers, solutions. Nat. Rev. Clin. Oncol. 14, 381–390 (2017).
doi: 10.1038/nrclinonc.2017.31
pubmed: 28290490
Del Paggio, J. C. et al. Evolution of the randomized clinical trial in the era of precision oncology. JAMA Oncol. 7, 728–734 (2021).
doi: 10.1001/jamaoncol.2021.0379
pubmed: 33764385
Templeton, A. J., Booth, C. M. & Tannock, I. F. Informing patients about expected outcomes: the efficacy–effectiveness gap. J. Clin. Oncol. 38, 1651–1654 (2020).
Horton, S. & Gauvreau, C. L. Cancer in low- and middle-income countries: an economic overview. In Cancer: Disease Control Priorities 3rd edn Vol. 3 (eds Gelband, H., Jha, P., Sankaranarayanan, R. & Horton, S.) (the World Bank, 2015).
Pramesh, C. S. et al. Choosing wisely India: ten low value or harmful practices that should be avoided in cancer care. Lancet Oncol. 20, e218–e223 (2019).
doi: 10.1016/S1470-2045(19)30092-0
pubmed: 30857957
Singh, A. G. et al. A prospective study to determine the cost of illness for oral cancer in India. ecancermedicalscience 15, 1252 (2021).
doi: 10.3332/ecancer.2021.1252
pubmed: 34267808
pmcid: 8241452
Del Paggio, J. C. et al. Delivery of meaningful cancer care: a retrospective cohort study assessing cost and benefit with the ASCO and ESMO frameworks. Lancet Oncol. 18, 887–894 (2017).
doi: 10.1016/S1470-2045(17)30415-1
pubmed: 28583794
Pitt, C., Goodman, C. & Hanson, K. Economic evaluation in global perspective: a bibliometric analysis of the recent literature. Health Econ. 25, 9–28 (2016).
doi: 10.1002/hec.3305
pubmed: 26804359
pmcid: 5042080
Haacker, M., Hallett, T. B. & Atun, R. On discount rates for economic evaluations in global health. Health Policy Plan. 35, 107–114 (2020).
doi: 10.1093/heapol/czaa073
pubmed: 31625564
Jamison, D. T. et al. Global health 2035: a world converging within a generation. Lancet 382, 1898–1955 (2013).
doi: 10.1016/S0140-6736(13)62105-4
pubmed: 24309475
Lorenz, K. A. et al. The Palliative Care—Promoting Access and Improvement of the Cancer Experience (PC-PAICE) project in India: a multisite international quality improvement collaborative. J. Pain Symptom Manage. 61, 190–197 (2021).
Ghoshal, A. et al. Implementation of an early palliative care referral program in lung cancer: a quality improvement project at the Tata Memorial Hospital, Mumbai, India. Indian J. Palliat. Care 27, 211–215 (2021).
doi: 10.25259/IJPC_394_20
pubmed: 34511786
pmcid: 8428894
Haines, A. & Jones, R. Implementing findings of research. BMJ 308, 1488–1492 (1994).
doi: 10.1136/bmj.308.6942.1488
pubmed: 8019284
pmcid: 2540317
Bodenheimer, T. The American health care system: the movement for improved quality in health care. N. Engl. J. Med. 340, 488–492 (1999).
doi: 10.1056/NEJM199902113400621
pubmed: 9971876
Schuster, M., McGlynn, E. & Brook, R. How good is the quality of medical care in the United States? Milbank Q. 76, 517–563 (1998).
doi: 10.1111/1468-0009.00105
pubmed: 9879302
pmcid: 2751100
Grol, R. Successes and failures in the implementation of evidence based guidelines in clinical practice. Med. Care 39, 46–54 (2001).
doi: 10.1097/00005650-200108002-00003
Alonge, O. et al. How is implementation research applied to advance health in low-income and middle-income countries? BMJ Glob. Health 4, e001257 (2019).
doi: 10.1136/bmjgh-2018-001257
pubmed: 30997169
pmcid: 6441291
Booth, C. M., Karim, S. & Mackillop, W. J. Real-world data: towards achieving the achievable in cancer care. Nat. Rev. Clin. Oncol. 16, 312–325 (2019).
doi: 10.1038/s41571-019-0167-7
pubmed: 30700859
World Health Organization. The DOTS Strategy for Controlling TB https://www.who.int/tb/publications/manual_for_participants_pp51_98.pdf (2021).
Sullivan, R., Pramesh, C. S. & Booth, C. M. Cancer patients need better care, not just more technology. Nature 549, 325–328 (2017).
doi: 10.1038/549325a
pubmed: 28933447
Ross, C. & Swetlitz, I. IBM pitched its Watson supercomputer as a revolution in cancer care. It’s nowhere close. STAT https://www.statnews.com/2017/09/05/watson-ibm-cancer/ (2017).
Pramesh, C. S., Badwe, R. A. & Sinha, R. K. The National Cancer Grid of India. Indian J. Med. Paediatr. Oncol. 35, 226–227 (2014).
doi: 10.4103/0971-5851.142040
pubmed: 25336795
pmcid: 4202620